Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar vs Actos in T2D and NYHA Class II Heart Failure
NCT00461058Phase 2Completed
- Sponsor
- Roche
- Start
- May 2007
- Primary completion
- Dec 2007
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of aleglitazar in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Roche. Primary endpoint: Incidence of cardiovascular death, hospitalization or clinic visit for heart failure with i.v. administration of diuretics at 26 weeks. Started May 2007; status: completed.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00461058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461058.